Abbott Laboratories (ABT) is Upgraded by Edward Jones to Buy

Abbott Laboratories (ABT) was Upgraded by Edward Jones to ” Buy”. Earlier the firm had a rating of “Hold ” on the company shares. Edward Jones advised their investors in a research report released on Jun 21, 2016.

Many Wall Street Analysts have commented on Abbott Laboratories. Company shares were Reiterated by RBC Capital Mkts on Apr 11, 2016 to “Outperform”, Firm has raised the Price Target to $ 48 from a previous price target of $45 .

On the company’s financial health, Abbott Laboratories reported $0.41 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Apr 20, 2016. Analyst had a consensus of $0.39. The company had revenue of $4885.00 million for the quarter, compared to analysts expectations of $4777.68 million. The company’s revenue was down -.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.47 EPS.

Abbott Laboratories opened for trading at $37.88 and hit $38.0661 on the upside on Monday, eventually ending the session at $37.75, with a gain of 0.96% or 0.36 points. The heightened volatility saw the trading volume jump to 77,07,311 shares. Company has a market cap of $55,460 M.

Investors should note that on Jun 10, 2016, Abbott Laboratories announced a cash dividend of $0.2600. The company’s management has announced Jul 13, 2016 as the ex-dividend date and fixed the record date on Jul 15, 2016. The payable date has been fixed on Aug 15, 2016.

In a different news, on Jun 17, 2016, Jared Watkin (Senior Vice President) sold 552 shares at $37.63 per share price. According to the SEC, on Jun 3, 2016, Brian B Yoor (Senior Vice President and CFO) sold 565 shares at $39.49 per share price. On Apr 29, 2016, Deepak S. Nath (Senior Vice President) sold 53 shares at $41.31 per share price, according to the Form-4 filing with the securities and exchange commission.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Abbott Laboratories

Leave a Reply

Abbott Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on Abbott Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.